{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Survivin+Vaccine", "query": { "intervention": "Survivin Vaccine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Survivin+Vaccine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T23:40:30.607Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00499083", "title": "Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "aromatase inhibition therapy", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "19 Years to 120 Years · Female only" }, "enrollment_count": 17, "start_date": "2006-05-01", "completion_date": "2010-01-28", "has_results": true, "last_update_posted_date": "2023-09-29", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 2, "location_summary": "Tampa, Florida • Omaha, Nebraska", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499083" }, { "nct_id": "NCT01416038", "title": "Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "DPX-Survivac", "type": "BIOLOGICAL" }, { "name": "low dose cyclophosphamide (oral)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ImmunoVaccine Technologies, Inc. (IMV Inc.)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 19, "start_date": "2011-12", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 5, "location_summary": "Buffalo, New York • Mineola, New York • Durham, North Carolina + 2 more", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Mineola", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01416038" }, { "nct_id": "NCT02851056", "title": "Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Survivin Vaccine", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" }, { "name": "Granulocyte-colony Stimulating Factor", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2016-09-27", "completion_date": "2018-08-09", "has_results": false, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02851056" }, { "nct_id": "NCT00470015", "title": "Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "MART-1a peptide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2007-03", "completion_date": "2013-01-02", "has_results": false, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470015" }, { "nct_id": "NCT05283109", "title": "ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma, Malignant" ], "interventions": [ { "name": "Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine", "type": "BIOLOGICAL" }, { "name": "Hiltonol", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-08-30", "completion_date": "2028-02-28", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283109" }, { "nct_id": "NCT00499577", "title": "Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "CMV pp65 peptide", "type": "BIOLOGICAL" }, { "name": "hTERT I540/R572Y/D988Y multipeptide vaccine", "type": "BIOLOGICAL" }, { "name": "pneumococcal polyvalent vaccine", "type": "BIOLOGICAL" }, { "name": "survivin Sur1M2 peptide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Maryland Greenebaum Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 56, "start_date": "2006-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499577" }, { "nct_id": "NCT03762291", "title": "Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CVD908ssb-TXSVN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-08-06", "completion_date": "2024-08-05", "has_results": false, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03762291" }, { "nct_id": "NCT01660529", "title": "Multi-peptide Vaccine With Basilixumab for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "hTERT", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-06", "completion_date": "2015-11-20", "has_results": false, "last_update_posted_date": "2019-06-25", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01660529" }, { "nct_id": "NCT02455557", "title": "SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "SVN53-67/M57-KLH Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2015-05-04", "completion_date": "2026-09-02", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02455557" }, { "nct_id": "NCT00573495", "title": "Multipeptide Vaccine for Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasm", "Breast Cancer", "Cancer of the Breast", "Carcinoma, Ductal" ], "interventions": [ { "name": "hTERT/Survivin Multi-Peptide Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2007-11", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2016-09-29", "last_synced_at": "2026-09-22T23:40:30.607Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573495" } ] }